Physicians' Academy for Cardiovascular Education
A road map consisting of 9 stages for the development and evaluation of AI predictive models was published recognizing the challenges that clinicians may face and providing them with practical tips to manage these challenges.
In a Danish cohort study, individuals aged ≥70 years achieved a similar relative risk reduction of major vascular events with lipid-lowering therapy for primary prevention of CVD as those aged <70 years.
In hospitalized acute HF patients, the number of non-cardiac comorbidities did not limit rapid uptitration of oral HF therapies, nor influence the beneficial effects of high-intensity care on 180-day HF rehospitalization or all-cause mortality compared with usual care.
What are you missing when treating your patients with heart failure and CKD become hyperkalemic? Experts discuss ways to avoid gaps in care.
The OCEANIC-AF study will be stopped early due to a lack of efficacy. The study investigates the effects of FXIa inhibitor asundexian compared to apixaban on the risk of stroke and systemic embolism in patients with AF at risk of stroke.
AHA 2023 In the POP-HT trial, self-monitoring of BP in combination with physician guided anti-hypertensive medication adjustment during the first 6 weeks postpartum led to improvements in BP up to 9 months after a hypertensive pregnancy.
AHA 2023 What are the long-term effects of a postpartum physician-guided BP lowering strategy in woman after hypertensive pregnancy? Paul Leeson shares the results of the POP-HT trial.
In the APOLLO-B trial, 12-month treatment with patisiran resulted in preserved functional capacity, health status, and quality of life in patients with transthyretin (ATTR) cardiac amyloidosis compared with placebo.
The ORION-5 trial, in which 56 patients with homozygous familial hypercholesterolemia (HoFH) were treated with inclisiran or placebo, did not meet its primary endpoint of LDL-c reduction at 150 days. The PCSK9 level did decrease in the inclisiran group.
AHA 2023 Andrew Bellinger talks about VERVE-101, a novel base editing medicine which makes a single base pair change in the PCSK9 gene to lower PCSK9 and LDL-c. He shares three important observations of the first-in-human study with VERVE-101 in patients with HeFH and ASCVD.
AHA 2023 To the suprise of the investigators of the AZALEA-TIMI 71 trial, the Data Safety Monitoring Committe recommended early termination of the phase 2 trial with the FXI inhibitor abelacimab in patients with AF. What are the findings of an interim analysis?
AHA 2023 “Non-adherence is a huge problem and probably the biggest barrier when it comes to hypertension control” says Florian Rader. He discusses the possibilities of ultrasound renal denervation in hypertension care.
